Supply and demand of medical cannabis in Germany after legalisation: exploring 12 months of data from an online dispensary

Background In April 2024, medical cannabis was removed from the list of narcotic drugs in Germany. This case study explores trends in the supply and demand of medical cannabis over a one-year period. Methods Information on available cannabis flower products (including product names, sales prices, stock quantities and THC and CBD concentrations) was regularly accessed from one online dispensary in Germany. Product demand was ascertained by differences in stock quantity over time. Accounting for the impact of %THC and prices, the supply and demand of medical cannabis were explored. Findings Between December 2024 (n=266) and November 2025 (n=401), the number of cannabis flower products available for purchase increased (total availability across the study period: n=996). Median %THC remained mostly stable, but the price per 10mg THC dropped by -0.003€ every week (95% Confidence Interval[CI]: -0.004 to -0.002€). Products with 20 to 29.9% THC made up more than two-thirds of total demand. Product demand quantities increased with every percentage point higher %THC (Incidence Rate Ratio[IRR]=1.13, 95% CI: 1.08 to 1.17) and decreased with every € higher price (IRR=0.59, 95% CI: 0.55 to 0.63; R 2 = 0.38). The price changed at least once for about every second product, with price reductions being associated with demand increases. Conclusions This case study suggests that a highly dynamic commercial market for medical cannabis is evolving in Germany. The increasing demand for cheap products with high %THC contrasts with the available evidence on the safe use of medical cannabis use. Current regulation of the medical cannabis market may not align with public health principles.

Authors

Institutions

Publication Details

Journal
International Journal of Drug Policy
Published
2026-06-27
DOI
https://doi.org/10.1016/j.drugpo.2026.105417
Primary Topic
Cannabis and Cannabinoid Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Supply and demand of medical cannabis in Germany after legalisation: exploring 12 months of data from an online dispensary

Carolin Kilian, Jakob Manthey, Uwe Verthein, Marc Giesmann
International Journal of Drug Policy
Cannabis and Cannabinoid Research
article

Supply and demand of medical cannabis in Germany after legalisation: exploring 12 months of data from an online dispensary

Carolin Kilian, Jakob Manthey, Uwe Verthein, Marc Giesmann
article en

Abstract

Background In April 2024, medical cannabis was removed from the list of narcotic drugs in Germany. This case study explores trends in the supply and demand of medical cannabis over a one-year period. Methods Information on available cannabis flower products (including product names, sales prices, stock quantities and THC and CBD concentrations) was regularly accessed from one online dispensary in Germany. Product demand was ascertained by differences in stock quantity over time. Accounting for the impact of %THC and prices, the supply and demand of medical cannabis were explored. Findings Between December 2024 (n=266) and November 2025 (n=401), the number of cannabis flower products available for purchase increased (total availability across the study period: n=996). Median %THC remained mostly stable, but the price per 10mg THC dropped by -0.003€ every week (95% Confidence Interval[CI]: -0.004 to -0.002€). Products with 20 to 29.9% THC made up more than two-thirds of total demand. Product demand quantities increased with every percentage point higher %THC (Incidence Rate Ratio[IRR]=1.13, 95% CI: 1.08 to 1.17) and decreased with every € higher price (IRR=0.59, 95% CI: 0.55 to 0.63; R 2 = 0.38). The price changed at least once for about every second product, with price reductions being associated with demand increases. Conclusions This case study suggests that a highly dynamic commercial market for medical cannabis is evolving in Germany. The increasing demand for cheap products with high %THC contrasts with the available evidence on the safe use of medical cannabis use. Current regulation of the medical cannabis market may not align with public health principles.

International Journal of Drug PolicyVol. 155
Universität Hamburg (DE), University of Southern Denmark (DK), University Medical Center Hamburg-Eppendorf (DE), Leipzig University (DE)
Bundesministerium für Gesundheit
Openalex Percentile: Top 9%
Cannabis and Cannabinoid Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.